Growth factors in Parkinson's disease

Progress in Growth Factor Research

Volumn 5, Issue 1, 1994, Pages 73-87

  Unsicker, Klaus ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

ciliary neurotrophic factor; dopaminergic neurons; epidermal growth factor; fibroblast growth factors; insulin like growth factors; interferon gamma; interleukins; neuropeptides; neurotrophins; Nigrostriatal system; transforming growth factor alpha

Indexed keywords

DOPAMINE; GROWTH PROMOTOR;

ANIMAL; HUMAN; NERVE CELL; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SUBSTANTIA NIGRA;

ANIMAL; DOPAMINE; GROWTH SUBSTANCES; HUMAN; NEURONS; PARKINSON DISEASE; SUBSTANTIA NIGRA; SUPPORT, NON-U.S. GOV'T;

EID: 0027953105     PISSN: 09552235     EISSN: None     Source Type: Journal    
DOI: 10.1016/0955-2235(94)90018-3     Document Type: Article

References (128)

1. The nerve growth factor 35 years later
2. Cell death during development of the nervous system
3. Trophic factors and neuronal survival
4. Release of dopamine from coaggregate cultures of mesencephalic tegmentum and corpus striatum
5. Specific stimulation of in vitro maturation of mesencephalic dopaminergic neurones by striatal membranes
6. Specific influence of striatal target neurons on the in vitro outgrowth of mesencephalic dopaminergic neurites: A morphological quantitive study
7. Soluble striatal extracts enhance development of mesencephalic dopaminergic neurons in vitro
8. Development and survival of neurons in dissociated fetal mesencephalic serum-free cell cultures: I. effects of cell density and of an adult mammalian striatal-derived neuronotrophic factor (SDNF)
9. Enhanced survival of cultured dopamine neurons by treatment with soluble extracts from chemically deafferentiated striatum of adult rat brain
10. Striatal extracts from patients with Parkinson's disease promote dopamine neuron growth in mesencephalic cultures
11. Regulation of the synthesis of nerve growth factor
12. Treatment with 6-hydroxydopamine and colchicine decreases nerve growth factor levels in sympathetic ganglia and increases them in the corresponding target tissues
13. Fibroblast growth factors: their roles in the central and peripheral nervous system
14. Increased basic fibroblast growth factor (bFGF) immunoreactivity at the site of focal brain wounds
15. Localization of basic fibroblast growth factor and its mRNA after CNS injury
16. A time course for the elevation of synthesis of fibroblast growth factor and one of its high affinity receptors (flg) following a localized cortical brain injury
17. Neurotrophin-5: a novel neurotrophic factor that activates trk and trk B
18. Molecular cloning and neurotrophic activities of a protein with structural similarities to nerve growth factor: developmental and topographic expression in the brain
19. Identification and characterization of a novel member of the nerve growth factor/brain-derived neurotrophic factor family
20. Mammalian neurotrophin-4: structure, chromosomal localization, tissue distribution, and receptor specificity
21. Molecular cloning of a human gene that is a member of the nerve growth factor family
22. Cloning and expression of a cDNA encoding a novel human neurotrophic factor
23. Neurotrophin-3: a neurotrophic factor related to NGF and BDNF
24. Primary structure and biological activity of a novel neurotrophic factor
25. 125I)β-nerve growth factor
26. Studies on the expression of beta NGF gene in the central nervous system: level and regional distribution of NGF mRNA suggest that NGF functions as a trophic factor for several neuron populations
27. Nerve growth factor and the neostriatum
28. Evidence for a physiological role of nerve growth factor in the central nervous system of neonatal rats
29. Brain-derived neurotrophic factor and neurotrophin-3 mRNAs are expressed in ventral midbrain regions containing dopaminergic neurons
30. Ventricular injection of nerve growth factor increases dopamine content in the striata of MPTP-treated mice
31. Selective and nonselective stimulation of central cholinergic and dopaminergic development in vitro by nerve growth factor, basic fibroblast growth factor, epidermal growth factor, insulin and the insulin-like growth factors I and II.
32. Cells that Express Brain-Derived Neurotrophic Factor mRNA in the Developing Postnatal Rat Brain
33. NT-3, BDNF and NGF in the developing rat nervous system: parallel as well as reciprocal patterns of expression
34. Regional distribution of brain-derived neurotrophic factor mRNA in the adult mouse brain
35. Dopaminergic stimulation upregulates the in vivo expression of brain-derived neurotrophic factor (BDNF) in the striatum
36. Molecular cloning of rat trkC and distribution of cells expressing messenger RNAs for members of the trk family in the rat central nervous system
37. Promotion of central cholinergic and dopaminergic neuron differentiation by brain-derived neurotrophic factor but not neurotrophin 3.
38. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra
39. The nature of the trophic action of brain-derived neurotrophic factor, des(1–3)-Insulin-like growth factor-1, and basic fibroblast growth factor on mesencephalic dopaminergic neurons developing in culture
40. Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: Involvement of the glutathione system
41. Brain-derived neurotrophic factor administration protects basal forebrain cholinergic but not nigral dopaminergic neurons from degenerative changes after axotomy in the adult rat brain.
42. Brain-derived neurotrophic factor augments rotational behavior and nigrostriatal dopamine turnover in vivo
43. Transient and persistent expression of NT-3/HDNF mRNA in the rat brain during postnatal development
44. Effects of BDNF and NT-3 on dopaminergic and GABAergic neurons in rat ventral mesencephalic cultures
45. Fibroblast growth factors: Their roles in the central and peripheral nervous system
46. Cytokines in neural regeneration
47. Expression of acidic and basic fibroblast growth factors in the substantia nigra of rat, monkey and human
48. Basic FGF is present in dopaminergic neurons of the ventral midbrain of the rat
49. Loss of basic fibroblast growth factor in substantia nigra neurons in Parkinson's disease
50. Endogenous expression of acidic and basic fibroblast growth factors in 1-methyl-4-phenyl-1,2,3,5-tetrahydropyridine (MPTP) lesioned mouse brain
51. Increased basic fibroblast growth factor (bFGF) immunoreactivity at the site of focal brain wounds
52. Basic FGF in the adult Brain: cellular distribution and response to entorhinal lesion and fimbria-fornix transection
53. Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction
54. Localization of FGF receptor mRNA in the adult rat central nervous system by in situ hybridization
55. bFGF undergoes receptor-mediated retrograde transport in CNS neurons
56. Fibroblast growth factor receptor-bearing neurons in the CNS: Identification by receptor-mediated retrograde transport
57. Apparent anterograde transport of basic fibroblast growth factor in the rat nigrostriatal dopamine system
58. Basic fibroblast growth factor promotes the survival and development of mesencephalic neurons in culture
59. 1-induced degeneration
60. Mitogenic effect of basic fibroblast growth factor on embryonic ventral mesencaphalic dopaminergic neurone precursors
61. Effect of basic fibroblast growth factor on neurons cultured from various regions of postnatal rat brain
62. The neurotrophic effects of fibroblast growth factors on dopaminergic neurons in vitro are mediated by mesencephalic glia
63. Fibroblast growth factors stimulate nerve growth factor synthesis and secretion by astrocytes
64. lesion-induced neuron death and neural regeneration
65. Basic FGF reverses chemical and morphological deficits in the nigrostriatal system of MPTP-treated mice
66. Basic FGF and its actions on neurons: A group account with special emphasis on the Parkinsonian brain
67. Effects of FGF-2 on dopaminergic neurons
68. Fibroblast growth factors and Parkinson's disease
69. 1: specificity and impact of culture conditions, non-dopaminergic neurons, and astroglial cells
70. FGF-2 modulates dopamine and dopamine-related striatal tranmitter systems in the intact and MPTP-lesioned mouse
71. Wirkungen des basischen Fibroblastenwachstumsfaktors (bFGF) auf neurotoxin- geschädigte Neurone des nigrostriatalen Systems von Maus und Ratte
72. Basic fibroblast growth factor enhances survival and sprouting of fetal dopaminergic cells implanted in the denervated caudate-putamen: preliminary observations
73. Basic fibroblast growth factor ameliorates rotational behavior of substantia nigra-transplanted rats with lesions of the dopaminergic nigrostriatal neurons
74. Insulin and insulin-like growth factors in the CNS
75. Differential expression of insulin-like growth factor genes in rat central nervous system
76. Autoradiographic localization of insulin receptors in rat brain: Prominence in olfactory and limbic areas
77. Visualization of IGF-II receptors in rat brain
78. Localization of binding sites for insulin-like growth factor I (IGF-I) in the rat brain by quantitative autoradiography
79. Isolation and characterization of variant IGF-1 and IGF-2 from adult human brain
80. Identification of gly pro-glu (GPE), the aminoterminal tripeptide of insulin-like growth factor I which is truncated in brain, as a novel neuroactive peptide
81. Transient IGF-I gene expression during the maturation of functionally related central projection neurons
82. Insulin-like growth factor I mRNA levels are developmentally regulated in specific regions of the rat brain
83. Expression of insulin-like growth factor I by astrocytes in response to injury
84. Insulin-like growth factor-I (somatomedin C) receptors in the rat brain: distribution and interaction with the hippocampal cholinergic system
85. Localization of Type I Insulin-Like Growth Factor Receptor Messenger RNA in the Adult Rat Brain byin SituHybridization
86. Insulin-like growth factor 1 (IGF-1) receptors in the human brain: quantitative autoradiographic localization
87. Epidermal growth factor stimulates DNA-synthesis of astrocytes in primary cerebellar cultures
88. Epidermal growth factor (EGF) stimulation of cultured brain cells. I. Enhancement of the developmental increase in glial enzymatic activity
89. Trophic stimulation of cultured neurons from neonatal rat brain by epidermal growth factor
90. The ontogeny of epidermal growth factor receptors during mouse development
91. Epidermal growth factor receptor immunoreactivity in rat brain. Development and cellular localization
92. Localization of immunoreactive epidermal growth factor receptors in human nervous system
93. Regional distribution and developmental expression of epidermal growth factor and transforming growth factor-α mRNA in mouse brain by a quantitative nuclease protection assay
94. Epidermal growth factor-like transforming growth factor. II. Interaction with epidermal growth factor receptors in human placental membranes and A 431 cells
95. EGF enhances the survival of dopamine neurons in rat embryonic mesencephalon primary cell culture
96. Epidermal growth factor exerts neuronotrophic effects on dopaminergic and GABAergic neurons: Comparison with basic fibroblast growth factor
97. Epidermal growth factor enhances striatal dopaminergic parameters in the 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine-treated mouse
98. Intraventricular infusion of epidermal growth factor restores dopaminergic pathway in hemiparkinsonian rats
99. Receptors for interleukin-1 (α and β) in mouse brain: mapping and neuronal localization in hippocampus
100. In situ histochemical localization of type I interleukin-1 receptor messenger RNA in the central nervous system, pituitary, and adrenal gland of the mouse
101. Regional and cellular codistribution of interleukin 1β and nerve growth factor mRNA in the adult rat brain: Possible relationship to the regulation of nerve growth factor synthesis
102. Interleukin-1 regulates synthesis of nerve growth factor in non-neuronal cells of rat sciatic nerve
103. Interleukin I expression is inducible by nerve growth factor in PC 12 pheochromocytoma cells
104. Interleukin-6 improves the survival of mesencephalic catecholaminergic and septal cholinergic neurons from postnatal, two-week-old rats in culture
105. Interleukin-6 as a neurotrophic factor for promoting the survival of cultured catecholaminergic neurons in a chemically defined medium from fetal and postnatal rat midbrains
106. Microglial conditioned medium promotes survival and development of cultured mesencephalic neurons from embryonic rat brain
107. Cytokines in context
108. Recovery in hemiparkinsonian rats following intrastriatal implantation of activated leukocytes
109. Behavioral and ECoG spectrum changes induced by intracerebral infusion of interferons and interleukin 2 in rats are antagonized by naloxone
110. Interleukin-1β and tumor necrosis factor alpha synergistically stimulate nerve growth factor (NGF) release from cultured rat astrocytes
111. Induction of manganous superoxide dismutase by tumor necrosis factor: possible protective mechanism
112. Transgenic mice with increased Cu/Zn-Superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity
113. Suppression of active neuronal death by immuno interferon
114. Cytokines in neural regeneration
115. Regional distribution, developmental changes, and cellular localization of CNTF-mRNA and protein in the rat brain
116. Ciliary neurotrophic factor (CNTF) prevents axotomy-induced degeneration of adult rat substantia nigra dopaminergic neurons
117. Gangliosides and brain repair
118. Administration of GM1 ganglioside restores the dopamine content in striatum after chronic treatment with MPTP
119. Treatment with GM1 Ganglioside Restores Striatal Dopamine in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Treated Mouse
120. GM1 ganglioside-induced recovery of nigrostriatal dopaminergic neurons after MPTP: an immunohistochemical study
121. Effect of GM1 ganglioside treatment on the recovery of dopaminergic nigrostriatal neurons after different types of lesion
122. Screening of adrenal medullary neuropeptides for putative neurotrophic effects
123. Muscle-derived differentiation factor increases expression of the tyrosine hydroxylase gene and enzyme activity in cultured dopamine neurons from the rat midbrain
124. Presynaptic transmitters and depolarizing influences regulate development of the substantia nigra in culture
125. Recovery from unilateral 6-hydroxydopamine lesion of substantia nigra promoted by the neurotachykinin substance P 1–11
126. Neurotensin increases tyrosine hydroxylase messenger RNA-positive neurons in substantia nigra after retrograde axonal transport